Protagonist Therapeutics, Inc.
PTGX
Rang in Aktien
#2247
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Aktienkurs
$138.50
Marktkapitalisierung
$8.96B
Veränderung (1 Tag)
3.02%
Veränderung (1 Jahr)
80.53%
Land
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategorie
Healthcare
Anzahl der ausstehenden Aktien von Protagonist Therapeutics, Inc. (PTGX)
Anzahl der ausstehenden Aktien zum June 2026: 65.94M
Laut den neuesten Finanzberichten und dem Aktienkurs von Protagonist Therapeutics, Inc. beträgt die aktuelle Anzahl der ausstehenden Aktien 65.94M. Am Ende von December 2023 hatte das Unternehmen 56.76M ausstehende Aktien. Die Anzahl der ausstehenden Aktien wird normalerweise durch Aktiensplits und Aktienrückkäufe beeinflusst.
Verlauf der ausstehenden Aktien von Protagonist Therapeutics, Inc. (PTGX) von 2014 bis 2026
Ausstehende Aktien am Ende jedes Jahres
| Jahr | Ausstehende Aktien | ändert |
|---|---|---|
| 2026 (TTM) | 65.94M | 7.10% |
| 2024 | 61.57M | 8.46% |
| 2023 | 56.76M | 15.74% |
| 2022 | 49.04M | 5.87% |
| 2021 | 46.32M | 34.67% |
| 2020 | 34.40M | 32.84% |
| 2019 | 25.89M | 15.78% |
| 2018 | 22.36M | 26.39% |
| 2017 | 17.69M | 172.15% |
| 2016 | 6.50M | 10.48% |
| 2015 | 5.88M | 0.00% |
| 2014 | 5.88M | 0.00% |
Ausstehende Aktien bei ähnlichen Unternehmen oder Wettbewerbern
| Unternehmen | Ausstehende Aktien | Unterschied | Land |
|---|---|---|---|
| 253.90M | 285.07% |
US
|
|
| 396.00M | 500.58% |
US
|
|
| 478.91M | 626.33% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -5.69% |
NL
|
